Liposomal Formulations in Clinical Use: An Updated Review
By Upendra Bulbake, Sindhu Doppalapudi, Nagavendra Kommineni, Wahid Khan. Pharmaceutics, 2017
1,769 citations recorded by the source corpus.
Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications. These closed bilayer phospholipid vesicles have witnessed many technical advances in recent years since their first development in 1965. Delivery of therapeutics by liposomes alters their biodistribution profile, which further enhances the therapeutic index of various drugs. Extensive research is being carried out using these nano drug delivery systems in diverse areas including the delivery of anti-cancer, anti-fungal, anti-inflammatory drugs and therapeutic genes. The significant contribution of liposomes as drug delivery systems in the healthcare sector is known by many clinical products, e.g., Doxil®, Ambisome®, DepoDur™, etc. This review provides a detailed update on liposomal technologies e.g., DepoFoam™ Technology, Stealth technology, etc., the formulation aspects of clinically used products and ongoing clinical trials on liposomes.
Subfields: Biomaterials, Molecular Biology, Pharmaceutical Science
View Paper: https://www.semanticscholar.org/paper/343c424960362bd5a138bdabe2ea1f76108b31ab
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. T. Caccamo
- M. Kiselev
- D. Lombardo
- W. Alshaer
- A. Al bawab
- M. Danaei
- R. Javanmard
- M. R. Mozafari
Citations in the corpus
- Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems (2018, background): “However, it is difficult to control the particle size distribution without considering the composition of the nanocarriers and the nature of the solvents and co-solvents used during their preparation [8,75,76].”
- Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine (2019, background): “However, before the premarket authorization, nanocarriers are subject to a range of preclinical and clinical validation by regulatory agencies, such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the USA.”
- Liposomes: structure, composition, types, and clinical applications (2022, methodology): “2 of cholesterol into liposomes is indispensable since cholesterol modulates membrane permeability, changes fluidity, and improves the stability of bilayer membranes in the presence of biological fluids such as blood and plasma [31, 32].”